Directed migration of smooth muscle cells to engineer plaque-resistant vein grafts

Journal of Endovascular Therapy

Volumn 12, Issue 6, 2005, Pages 667-675

  Amabile, Philippe G ^a   Wang, David S ^a   Kao, Edward Y ^a   Lee, Jane ^a   Elkins, Christopher J ^a   Yuksel, Eser ^b   Hilfiker, Paul R ^a   Waugh, Jacob M ^a   Dake, Michael D ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Extracellular matrix; Neointima; Rabbit model; Saphenous vein graft; Smooth muscle cells; Tissue engineering; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; ELASTIN; MACROGOL; MICROSPHERE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; INFLAMMATORY INFILTRATE; MACROPHAGE; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS; THROMBUS; TISSUE ENGINEERING; VEIN GRAFT;

ANALYSIS OF VARIANCE; ANIMALS; CELL DIVISION; CELL MOVEMENT; MALE; MICROSPHERES; MUSCLE, SMOOTH, VASCULAR; RABBITS; SAPHENOUS VEIN; TIME FACTORS; TISSUE ENGINEERING; TISSUE PLASMINOGEN ACTIVATOR; TUNICA INTIMA; TUNICA MEDIA; VASCULAR SURGICAL PROCEDURES;

EID: 30744479207     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/04-1268Ra.1     Document Type: Article

References (27)

1. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997;337:365-372.
2. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97: 916-931.
3. Allaire E, Clowes AW. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg. 1997;63:582-591.
4. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation. 1992;86:723-729.
5. Libby P, Tanaka H. The molecular bases of restenosis. Prog Cardiovasc Dis. 1997;40:97-106.
6. Holifield B, Helgason T, Jemelka S, et al. Differentiated vascular myocytes: are they involved in neointimal formation? J Clin Invest. 1996;97:814-825.
7. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969-1976.
8. Lee DP, Lo S, Forster K, Yeung AC, et al. Clinical applications of brachytherapy for the prevention of restenosis. Vasc Med. 1999;4:257-268.
9. Batchelor WB, Robinson R, Strauss BH. The extracellular matrix in balloon arterial injury: a novel target for restenosis prevention. Prog Cardiovasc Dis. 1998;41:35-49.
10. Forough R, Koyama N, Hasenstab D, et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996;79:812-820.
11. Yoshida Y, Mitsumata M, Ling G, et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann N Y Acad Sci. 1997;811:459-470.
12. Johnson TJ. TNK-tPA: a new thrombolytic for treatment of acute myocardial infarction. SDJ Med. 2000;53:185-186.
13. Skinner MP, Raines EW, Ross R. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol. 1994;145: 1070-1081.
14. Bingley JA, Campbell JH, Hayward IP, et al. Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Ann N Y Acad Sci. 1997;811:238-244.
15. Ooyama T, Fukuda K, Oda H, et al. Substratum-bound elastin peptide inhibits aortic smooth muscle cell migration in vitro. Arteriosclerosis. 1987;7:593-598.
16. Carmeliet P, Moons L, Ploplis V, et al. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200-208.
17. Liotta LA, Goldfarb RH, Brundage R, et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981;41:4629-4636.
18. He CS, Wilhelm SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA. 1989;86:2632-2636.
19. Rabbani LE, Johnstone MT, Rudd MA, et al. PPACK attenuates plasmin-induced changes in endothelial integrity. Thromb Res. 1993;70: 425-436.
20. Hilfiker PR, Waugh JM, Li-Hawkins JJ, et al. Enhancement of neointima formation with tissue-type plasminogen activator. J Vasc Surg. 2001; 33:821-828.
21. Yuksel E, Weinfeld AB, Cleek R, et al. De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: a novel concept and capability. Plast Reconstr Surg. 2000;105:1721-1729.
22. Waugh JM, Li-Hawkins J, Yuksel E, et al. Thrombomodulin overexpression to limit neo-intima formation. Circulation. 2000;102:332-337.
23. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-429.
24. Yuksel E, Weinfeld AB, Cleek R, et al. Increased free fat-graft survival with the long-term, local delivery of insulin, insulin-like growth factor-I, and basic fibroblast growth factor by PLGA/PEG microspheres. Plast Reconstr Surg. 2000; 105:1712-1720.
25. Elkins CJ, Waugh JM, Amabile PG, et al. Development of a platform to evaluate and limit instent restenosis. Tissue Eng. 2002;8:395-407.
26. Hinek A, Boyle J, Rabinovitch M. Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced "shed-ding" of the 67-kDa cell surface elastin binding protein. Exp Cell Res. 1992;203:344-353.
27. Yuksel E, Weinfeld AB, Cleek R, et al. Augmentation of adipofascial flaps using the long-term local delivery of insulin and insulin-like growth factor-1. Plast Reconstr Surg. 2000;106:373-382.